Pre-made Vanucizumab biosimilar ( Bispecific mAb, anti-ANGPT2;VEGFA therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-612
Anti-ANGPT2;VEGFA therapeutic antibody (Pre-made Vanucizumab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-ANGPT2;VEGFA therapeutic antibody (Pre-made Vanucizumab biosimilar,Bispecific mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ|
|99% SI Structure||None;None|
|95-98% SI Structure||None;6bft:AB:HL/1cz8:HL:YX|
|Conditions Discontinued||Solid tumours;Colorectal cancer|